See-Hwee Yeo1, Zheng-Jie Ian Lim1, Jia Mao1, Wai-Ping Yau2. 1. Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore, 117543, Singapore. 2. Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore, 117543, Singapore. phaywp@nus.edu.sg.
Abstract
BACKGROUND AND OBJECTIVE: Pilot trials have suggested that pharmacotherapy may aid stroke recovery. The aim of this study was to systematically review the effects of antidepressants, anti-Alzheimer drugs, anti-Parkinson drugs, central nervous system (CNS) stimulants and piracetam on gross motor function, cognition, disability, dependency and quality of life (QOL) after stroke. METHODS: PubMed, EMBASE and the Cochrane Central Register of Controlled Trials databases were searched, and 44 randomized controlled trials that compared outcomes of interest between drug treatment and placebo or no treatment were included. For each study, standardized mean difference (SMD) or mean difference (MD) with 95% confidence interval (CI) were calculated. Meta-analyses were conducted to pool results using either the fixed-effects or random-effects model. RESULTS: Selective serotonin reuptake inhibitors (SSRIs) improved gross motor function (SMD 0.54, 95% CI 0.22-0.85; three studies), disability (SMD 0.49, 95% CI 0.32-0.66; 14 studies) and QOL (MD 6.46, 95% CI 4.71-8.22; two studies), but there was insufficient evidence for their use in enhancing global cognition (SMD 0.23, 95% CI -0.01 to 0.46; five studies) and dependency (risk ratio 0.81, 95% CI 0.68-0.97; one fluoxetine study). In particular, gross motor function was improved by fluoxetine (SMD 0.64, 95% CI 0.31-0.98; two studies), while disability was improved by paroxetine (SMD 1.05, 95% CI 0.63-1.46; two studies), citalopram (SMD 0.51, 95% CI 0.08-0.93; two studies) and fluoxetine (SMD 0.41, 95% CI 0.22-0.60; nine studies). There is insufficient evidence for the use of anti-Alzheimer drugs, anti-Parkinson drugs, CNS stimulants and piracetam to promote stroke recovery. CONCLUSIONS: Administration of SSRIs may improve gross motor function, reduce disability and enhance QOL for patients recovering from stroke.
BACKGROUND AND OBJECTIVE: Pilot trials have suggested that pharmacotherapy may aid stroke recovery. The aim of this study was to systematically review the effects of antidepressants, anti-Alzheimer drugs, anti-Parkinson drugs, central nervous system (CNS) stimulants and piracetam on gross motor function, cognition, disability, dependency and quality of life (QOL) after stroke. METHODS: PubMed, EMBASE and the Cochrane Central Register of Controlled Trials databases were searched, and 44 randomized controlled trials that compared outcomes of interest between drug treatment and placebo or no treatment were included. For each study, standardized mean difference (SMD) or mean difference (MD) with 95% confidence interval (CI) were calculated. Meta-analyses were conducted to pool results using either the fixed-effects or random-effects model. RESULTS: Selective serotonin reuptake inhibitors (SSRIs) improved gross motor function (SMD 0.54, 95% CI 0.22-0.85; three studies), disability (SMD 0.49, 95% CI 0.32-0.66; 14 studies) and QOL (MD 6.46, 95% CI 4.71-8.22; two studies), but there was insufficient evidence for their use in enhancing global cognition (SMD 0.23, 95% CI -0.01 to 0.46; five studies) and dependency (risk ratio 0.81, 95% CI 0.68-0.97; one fluoxetine study). In particular, gross motor function was improved by fluoxetine (SMD 0.64, 95% CI 0.31-0.98; two studies), while disability was improved by paroxetine (SMD 1.05, 95% CI 0.63-1.46; two studies), citalopram (SMD 0.51, 95% CI 0.08-0.93; two studies) and fluoxetine (SMD 0.41, 95% CI 0.22-0.60; nine studies). There is insufficient evidence for the use of anti-Alzheimer drugs, anti-Parkinson drugs, CNS stimulants and piracetam to promote stroke recovery. CONCLUSIONS: Administration of SSRIs may improve gross motor function, reduce disability and enhance QOL for patients recovering from stroke.
Authors: Won Hyuk Chang; Yun H Park; Suk Hoon Ohn; Chang-hyun Park; Peter K W Lee; Yun-Hee Kim Journal: Neuropsychol Rehabil Date: 2011-06-30 Impact factor: 2.868
Authors: R G Robinson; S K Schultz; C Castillo; T Kopel; J T Kosier; R M Newman; K Curdue; G Petracca; S E Starkstein Journal: Am J Psychiatry Date: 2000-03 Impact factor: 18.112
Authors: Carolee J Winstein; Joel Stein; Ross Arena; Barbara Bates; Leora R Cherney; Steven C Cramer; Frank Deruyter; Janice J Eng; Beth Fisher; Richard L Harvey; Catherine E Lang; Marilyn MacKay-Lyons; Kenneth J Ottenbacher; Sue Pugh; Mathew J Reeves; Lorie G Richards; William Stiers; Richard D Zorowitz Journal: Stroke Date: 2016-05-04 Impact factor: 7.914
Authors: Dávid Kovacs; Xénia Gonda; Péter Petschner; Andrea Edes; Nóra Eszlari; György Bagdy; Gabriella Juhasz Journal: Ann Gen Psychiatry Date: 2014-06-13 Impact factor: 3.455
Authors: F Chollet; J Rigal; P Marque; M Barbieux-Guillot; N Raposo; V Fabry; J F Albucher; J Pariente; I Loubinoux Journal: Curr Neurol Neurosci Rep Date: 2018-10-23 Impact factor: 5.081
Authors: Melissa Lamar; Ramon A Durazo-Arvizu; Carlos J Rodriguez; Robert C Kaplan; Marisa J Perera; Jianwen Cai; Rebeca A Espinoza Giacinto; Hector M González; Martha L Daviglus Journal: J Int Neuropsychol Soc Date: 2019-09-23 Impact factor: 2.892
Authors: Melissa Lamar; Adeline León; Karina Romo; Ramon A Durazo-Arvizu; Shruti Sachdeva; Richard B Lipton; Krista M Perreira; Linda C Gallo; Jianwen Cai; Tasneem Khambaty; Jessica Carrasco; Maria M Llabre; Lisa T Eyler; Martha L Daviglus; Hector M González Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Stefano Paolucci; Marco Iosa; Paola Coiro; Vincenzo Venturiero; Anna Savo; Domenico De Angelis; Giovanni Morone Journal: Front Neurol Date: 2019-08-27 Impact factor: 4.003